If your like of of the millions of Americans expected to get corona virus this year you may be in luck, but only if you have money.
On Monday afternoon big orange scary retard gave Gilead Sciences “orphan drug stats for its antiviral drug, Remdesivir. The “orphan” status allows the pharmaceutical company to profit exclusively for seven years from the product, which is one of dozens being tested as a possible treatment for Covid-19, the disease caused by the new coronavirus.
Stressed out over all this corona virus mess.
The Food and Drug Administration gave an experimental medicine called remdesivir to treat COVID-19 what's called orphan drug status on Monday.
To qualify for an orphan designation, drug companies must show that their product will treat a population of fewer than 200,000 patients or that it would be unprofitable.
With more than 52,000 confirmed U.S. cases of COVID-19 reported as of Tuesday afternoon, the illness is under the technical threshold for a rare disease. But cases are rising quickly and it seems inevitable that they will surpass 200,000.
The agency's decision would provide lucrative incentives to the drug's maker, Gilead Sciences, and could keep lower-priced generic versions of the medicine off the market for several years if remdesivir is approved for use, public health advocates say.
Remdesivir is an intravenous, antiviral medicine that is being studied in clinical trials around the world as a possible treatment for COVID-19.
Clinical trials for remdesivir as a COVID-19 treatment got started in China in early February. Tests of the drug are now enrolling patients elsewhere, including the United States.